← Back to Search

Monoclonal Antibodies

MGD019 for Cervical Cancer

Phase 2
Recruiting
Led By Amir Jazeri, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 18 years at time of study entry
Eastern Cooperative Oncology Group performance status 0 - 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through the study completion an average of 1 year.
Awards & highlights

Study Summary

This trial will test if MGD019 can help control cervical cancer in patients who have not yet received treatment.

Who is the study for?
This trial is for adults over 18 with confirmed recurrent, metastatic, or persistent cervical cancer who haven't had treatment yet. They must be able to follow the study protocol and have adequate organ function. Women should be post-menopausal or not pregnant and everyone must meet certain blood count criteria. Those vaccinated against COVID-19 need to wait at least 14 days before starting the trial.Check my eligibility
What is being tested?
MGD019 is being tested to see if it can control advanced cervical cancer in patients who are receiving their first treatment. The study will monitor how well this drug works and its safety in participants meeting specific health criteria.See study design
What are the potential side effects?
While specific side effects of MGD019 aren't listed here, similar drugs often cause immune-related reactions, fatigue, nausea, skin issues, and may affect liver enzymes. Participants will be monitored closely for any adverse effects during the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I am fully active or can carry out light work.
Select...
I am post-menopausal or not pregnant if pre-menopausal.
Select...
My condition cannot be cured with surgery or radiation.
Select...
My cervical cancer has come back or spread, confirmed by biopsy or CT scan.
Select...
My blood clotting tests are within normal limits, unless I'm on blood thinners.
Select...
My cancer is either squamous cell, adenosquamous, or adenocarcinoma.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through the study completion an average of 1 year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through the study completion an average of 1 year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To establish overall survival (OS)

Trial Design

1Treatment groups
Experimental Treatment
Group I: MGD019Experimental Treatment1 Intervention
Participants will receive MGD019 by vein over about 30 minutes on Day 1 of each cycle

Find a Location

Who is running the clinical trial?

MacroGenicsIndustry Sponsor
48 Previous Clinical Trials
5,054 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
2,962 Previous Clinical Trials
1,803,324 Total Patients Enrolled
Amir Jazeri, MDPrincipal InvestigatorM.D. Anderson Cancer Center

Media Library

MGD019 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05475171 — Phase 2
Cervical Cancer Research Study Groups: MGD019
Cervical Cancer Clinical Trial 2023: MGD019 Highlights & Side Effects. Trial Name: NCT05475171 — Phase 2
MGD019 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05475171 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How reliable is MGD019 in terms of safety for humans?

"As it is a Phase 2 trial, with some evidence of safety but no proof yet that the medication works effectively, MGD019 was assigned a score of two on our team's scale."

Answered by AI

Is this trial currently welcoming participants?

"Data on clinicaltrials.gov indicates that recruiting for this medical trial has ceased as of September 19th 2022, when it was last updated; however, 561 other trials are presently accepting patients at the present moment. The study first appeared on January 31st 2023."

Answered by AI
~26 spots leftby Jun 2026